Brian Daniel Webster Sells 8,948 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $22.60, for a total transaction of $202,224.80. Following the completion of the transaction, the insider directly owned 540,132 shares in the company, valued at approximately $12,206,983.20. This represents a 1.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.92, for a total transaction of $311,366.64.
• On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.72, for a total transaction of $178,511.04.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00.
• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.96, for a total transaction of $314,400.00.

Kestra Medical Technologies Trading Up 8.1%

Shares of NASDAQ:KMTS opened at $25.93 on Wednesday. The company has a market cap of $1.52 billion, a P/E ratio of -10.71 and a beta of 0.58. The stock’s 50-day moving average is $22.70 and its 200-day moving average is $22.51. Kestra Medical Technologies, Ltd. has a 52-week low of $14.10 and a 52-week high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. Equities research analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Kestra Medical Technologies News Summary

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Analyst sentiment remains mixed but includes three Buy ratings, with a consensus price target of $27.83. BTIG Research raised its target to $32 and maintained a Buy rating, while Wolfe Research set a $30 objective. Kestra Medical Technologies insider-selling report
• Positive Sentiment: Several institutional investors increased their positions, including Russell Investments Group, Brown Brothers Harriman, Rhumbline Advisers and New Jersey’s Police & Firemen’s Retirement System. These additions provide some support for institutional interest in KMTS.
• Neutral Sentiment: Executives and insiders sold roughly 103,000 shares worth more than $2.2 million between July 30 and August 3. Sellers included CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran. Because the filings specify tax-related sales, the transactions may reflect equity vesting rather than discretionary selling.
• Negative Sentiment: The number of sellers, including the CFO, could still weigh on investor sentiment and raise concerns about management ownership. Kestra’s latest quarterly loss of $0.67 per share exceeded the expected loss of $0.59, while revenue was $28.64 million and the company remains unprofitable.

Institutional Trading of Kestra Medical Technologies

Several hedge funds have recently modified their holdings of KMTS. Russell Investments Group Ltd. increased its holdings in shares of Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after buying an additional 474 shares in the last quarter. Brown Brothers Harriman & Co. boosted its holdings in shares of Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares in the last quarter. Rhumbline Advisers grew its position in Kestra Medical Technologies by 7.3% during the 3rd quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock worth $307,000 after acquiring an additional 874 shares during the last quarter. Farther Finance Advisors LLC acquired a new stake in Kestra Medical Technologies during the 4th quarter valued at $31,000. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in Kestra Medical Technologies by 34.6% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock valued at $144,000 after purchasing an additional 1,392 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have commented on KMTS. Oppenheimer started coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Wall Street Zen lowered shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. BTIG Research increased their price target on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a report on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $27.83.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.